這是一項在中國兒童癌症協作組（CCCG）內進行的前瞻性、多中心研究。本研究旨在評估加入三種新型藥物 dasatinib、venetoclax 及 homoharringtonine 能否提高新確診T細胞急性淋巴細胞白血病（T-ALL）兒童患者的微量殘留病灶（MRD）陰性緩解率、改善無事件存活期（EFS）及降低累積復發發生率（CIR）
適應症：Acute Lymphoblastic Leukemia、Childhood Leukemia, Acute Lymphoblastic、T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
收案條件
納入條件
- Age older than 1 month to younger than 18 years.
- Diagnosis of acute lymphoblastic leukemia by bone marrow morphology.
- Diagnosis of T-ALL by immunophenotyping.
排除條件
- B-ALL
- Acute leukemias of ambiguous lineage diagnosed according to WHO or EGIL criteria.
- ALL evolved from chronic myeloid leukemia (CML).
- Down's syndrome, or major congenital or hereditary disease with organ dysfunction
- Secondary leukemia
- Known underlying congenital immunodeficiency or metabolic disease
- Congenital heart disease with cardiac insufficiency.
- Treated with glucocorticoids for ≥14 days, or ABL kinase inhibitors for \> 7 days within one month before enrollment, or any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
- Severe malnutrition, active infections, heart failure, or chemotherapy intolerance.
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。